Japanese pharmaceutical company Takeda has partnered with Hyderabad-based Biological E Ltd to manufacture its dengue vaccine. This collaboration aims to bolster the fight against dengue fever, a pressing global health concern. The World Health Organization (WHO) has set a target of achieving zero case-fatality rate due to dengue by 2030, and this partnership aligns with this goal.
Through this partnership, Takeda and Biological E will significantly expand their manufacturing capabilities, ensuring a reliable global supply of the dengue vaccine. Biological E will increase its production capacity to reach 50 million doses annually, while Takeda aims to manufacture 100 million doses each year within the next decade.
As part of the partnership, Biological E will establish a manufacturing facility in Hyderabad that will house the production of the dengue vaccine. Takeda President of the Global Vaccine Business Unit, Gary Dubin, expressed enthusiasm, recognizing Biological E's expertise in vaccine manufacturing and unwavering support for public health programs worldwide.
Dengue fever is the fastest-spreading mosquito-borne viral disease, with nearly half of the world's population at risk. In India and Southeast Asia alone, 1.3 billion people reside in dengue-endemic regions, with Thailand, India, and Indonesia among the most affected countries. This partnership between Takeda and Biological E will play a pivotal role in combating dengue on a global scale by enhancing vaccine accessibility in endemic regions.